文献速递银屑病与炎症性皮肤病

乌司奴单抗启动与早期严重心血管事件风险的病例-时间-对照研究

Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该研究利用法国国家健康保险数据库,纳入2010年4月至2016年12月暴露于乌司奴单抗的9290例患者,采用病例-时间-对照设计评估启动乌司奴单抗与严重心血管事件(SCE)的关联。结果显示高心血管风险患者中启动治疗与SCE风险显著相关(OR 4.17, 95%CI 1.19-14.59),低风险患者无显著关联(OR 0.30, 95%CI 0.03-3.13)。提示高心血管风险患者使用乌司奴单抗需谨慎。

要点

  • 高心血管风险患者启动乌司奴单抗后SCE风险显著升高(OR 4.17)。
  • 低心血管风险患者未观察到显著关联(OR 0.30)。
  • 处方乌司奴单抗前应评估患者心血管风险。

核心结论

  • 启动乌司奴单抗治疗可能在高心血管风险患者中触发严重心血管事件。

主要发现

  • 9290例患者中179例发生SCE(65例急性冠脉综合征、68例不稳定型心绞痛、46例卒中)。
  • 高心血管风险患者中启动乌司奴单抗与SCE显著相关(OR 4.17; 95%CI 1.19-14.59)。
  • 低心血管风险患者中无显著关联(OR 0.30; 95%CI 0.03-3.13)。

临床怎么用

  • 对高心血管风险患者处方乌司奴单抗时应谨慎,并评估心血管风险。

局限性

  • 观察性设计限制了研究结果的解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe psoriasis, psoriatic arthritis, and Crohn disease. In 2011, a meta-analysis of randomized clinical trials reported a potential risk of severe cardiovascular events (SCEs) within the first few months after the initiation of anti-IL-12/23p40 antibodies. OBJECTIVE: To assess whether the initiation of ustekinumab treatment is associated with increased risk of SCEs. DESIGN, SETTING, AND PARTICIPANTS: This case-time-control study used data from the French national health insurance database, covering 66 million individuals, on all patients exposed to ustekinumab between April 1, 2010, and December 31, 2016, classified according to their cardiovascular risk level (high- and low-risk strata). The risk period was the 6 months before the SCE, defined as acute coronary syndrome or stroke, and the reference period was the 6 months before the risk period. Statistical analysis was performed from September 20, 2017, to July 6, 2018. EXPOSURE: The initiation of ustekinumab treatment was screened during the risk and reference periods. MAIN OUTCOMES AND MEASURES: Odds ratios for the risk of SCE after the initiation of ustekinumab treatment were calculated. RESULTS: Of the 9290 patients exposed to ustekinumab (4847 men [52%]; mean [SD] age, 43 [14] years), 179 experienced SCEs (65 cases of acute coronary syndrome, 68 cases of unstable angina, and 46 cases of stroke). Among patients with a high cardiovascular risk, a statisically significant association between initiaton of ustekinumab treatment and SCE occurrence was identified (odds ratio, 4.17; 95% CI, 1.19-14.59). Conversely, no statistically significant association was found among patients with a low cardiovascular risk (odds ratio, 0.30; 95% CI, 0.03-3.13). CONCLUSIONS AND RELEVANCE: This study suggests that the initiation of ustekinumab treatment may trigger SCEs among patients at high cardiovascular risk. In line with the current mechanistic models for atherosclerotic disease, the period after the initiation of anti-IL-12/23p40 may be associated with atherosclerotic plaque destabilization via the inhibition of helper T cell subtype 17. Although the study interpretation is limited by its observational design, these results suggest that caution may be needed in the prescription of ustekinumab to patients at high cardiovascular risk.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Poizeau F, Nowak E, Kerbrat S, et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020. PMID: 32902568. doi:10.1001/jamadermatol.2020.2977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。